Article

August 22, 2014

US Chief Technology Officer Todd Park Leaving His Post

Todd Park, well-known in healthcare IT circles as a founder of Athenahealth and Castlight Health, is leaving his post as White House chief technology officer by year-end, Fortune is reporting..

Todd Park, well-known in healthcare IT circles as a founder of Athenahealth and Castlight Health, is leaving his post as White House chief technology officer by year-end,

.

Fortune is reporting.

Park became chief technology officer at HHS in 2009 and moved up to his current post in 2012, assuming a

made to

after its troubled launch.

Source: ModernHealthcare

Read the full story:

lead role in the fixes HealthCare.gov

http://bit.ly/1mvYn6l

Related Videos

John Michael O'Brien, PharmD, MPH

4 experts are featured in this series.

5 experts are featured in this series

5 experts are featured in this series

Richard J. Nowak, MD, MS, Yale School of Medicine

4 experts are featured in this series.

Naim Alkhouri, MD

Christine Funke, MD

Related Content

NYOH’s Doyle on Joining OneOncology: What We Value the Most Is Culture

April 25th 2025

NYOH’s Doyle on Joining OneOncology: What We Value the Most Is Culture

New York Oncology and Hematology becomes the 27th practice in OneOncology.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

US Tariffs | Image credit: Andrii - stock.adobe.com

April 25th 2025

Trump Tariffs on Pharmaceuticals Risk Causing Higher Costs, Drug Shortages

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Anatomy of colon model | Image credit: M+Isolation+Photo - stock.adobe.com

April 24th 2025

TyG-BMI Index Predicts Colorectal Cancer Risk, Study Finds

A new analysis links higher triglyceride-glucose (TyG) and TyG–body mass index (TyG-BMI) levels to increased colorectal cancer (CRC) risk, especially among women, but not mortality.

Related Content

NYOH’s Doyle on Joining OneOncology: What We Value the Most Is Culture

April 25th 2025

NYOH’s Doyle on Joining OneOncology: What We Value the Most Is Culture

New York Oncology and Hematology becomes the 27th practice in OneOncology.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

US Tariffs | Image credit: Andrii - stock.adobe.com

April 25th 2025

Trump Tariffs on Pharmaceuticals Risk Causing Higher Costs, Drug Shortages

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Anatomy of colon model | Image credit: M+Isolation+Photo - stock.adobe.com

April 24th 2025

TyG-BMI Index Predicts Colorectal Cancer Risk, Study Finds

A new analysis links higher triglyceride-glucose (TyG) and TyG–body mass index (TyG-BMI) levels to increased colorectal cancer (CRC) risk, especially among women, but not mortality.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions